ANTI-IDIOTYPE ANTIBODIES INDUCED BY SYNTHETIC POLYPEPTIDES

Abstract: Chemically synthesized polypeptides having amino acid residue sequences that substantially correspond to the amino acid residue sequences of particular variable or hyperviable regions of immunoglobulins, when administered alone or as polymers or as conjugates bound to carriers, induce the production of anti-idiotype antibodies of predetermined specificities.

Description: ANTI-IDIOTYPE ANTIBODIES INDUCED BY SYNTHETIC POLYPEPTIDES Description Technical Field The present invention relates to chemically synthesized polypeptides having amino acid residue sequences that substantially correspond to the amino acid residue sequences of particular variable or hypervariable regions of immunoglobulins, and which, when administered alone or as polymers or as conjugates bound to carriers, induce the production of anti-idiotype antibodies of predetermined specificities. Background An antibody is an immunoglobulin molecule that has a specific amino acid sequence and thus binds only with the antigen that induced its synthesis (its immunogen) or with a closely related antigen (or immunogen) . Immunoglobulin molecules include two kinds of polypeptide chains. Each molecule consists of larger identical polypeptide chains referred to as heavy chains (H chains) and two identical smaller ones referred to as light chains (L chains) . These polypeptide chains are held together by disulfide bonds and by noncovalent bonds, which are primarily hydrophobic. The heavy and light, polypeptide chains are synthesized iri vjvo on separate riboso es, assembled in the cell, and are secreted as an intact immunoglobulin molecule. The understanding of the structure and function of immunoglobulins has been facilitated by studies of fragments produced by enzymatic cleavage of the antibody molecule. For example, treatment of an antibody molecule with the enzyme papain produces two antigen-binding fragments (designated "Fab") and a complement-binding fragment (designated "Fc") , which contains no antigen-binding capability but determines important biological characteristics of the intact immunoglobulin molecule. Treatment of an antibody molecule with the enzyme pepsin, on the other hand, produces a single antigen-binding fragment [designated "F(ab*) 2 "] and a somewhat smaller complement-binding fragment (also designated "Fc") . The constant region of H chains allows the differentiation of immunoglobulins into classes and subclasses and confers certain biological properties such as the ability to activate complement, to cross the placenta, and to bind to polymorphonuclear -leukocytes or macrophages. In particular, five immunoglobulin classes (IgG, IgA, IgM, IgD, and igE) are recognized on the basis of structural differences of their heavy chains including the amino acid sequence and length of the polypeptide chain. The antigenic determinants on the heavy chains -also permit the identification and quantitation of the immunoglobulin classes by immunochemical assay techniques. The amino-terminal half of the light chains and the amino-terminal quarter of the heavy chains of an immunoglobulin molecule vary in their amino acid sequence and are termed the variable regions (V regions) of the polypeptide chains. Portions of the V region of one heavy and of one light polypeptide chain constitute the site for antigen binding. A considerable variation of the amino acid sequence of the variable region of an immunoglobulin molecule can exist which produces the many different antibody specificities. A region of extreme variability in the primary sequence within a variable region is called a hypervariable region. Capra et al. , Proc. Natl. Acad. Sci. USA, 71, 845 (1974) . The specificity of the molecular binding site of an antibody is termed its idiotype. The term idiotype denotes the unique variable (V) region sequences produced by each type of antibody-forming cell. An antibody having a binding site specificity for the binding site of another antibody is termed an anti-idiotype antibody. The same amino acid sequence variation that produces the antigen binding specificity of an immunoglobulin also determines which idiotypic determinants are present. Thus, particular idiotypes are almost invariably associated with immunoglobulins of a particular specificity. As such, idiotypes can serve as antigenic markers for immunoglobulins with a particular specificity and, by virtue of their surface immunoglobulin, B lymphocytes of the same specificity. The terms "cross-reactive" and "cross-reactivity" refer to the ability of an antibody to bind antigens other than its idio-specific antigen. Cross-reactive anti-idiotype antibodies can be divided into two major groups. One group comprises those anti-idiotype antibodies that recognize idiotypic antigenic determinants that are associated with specific amino acid sequences in the heavy and light chain variable regions. Anti-idiotype antibodies of this group often reflect the action of inherited immunoglobulin structural genes. Consequently, these antibodies do not cross-react in subjects that are not genetically similar. The second group includes anti-idiotype antibodies that are cross-reactive to the internal image of the antigen. This type of anti-idiotypic antibody is elicited by immunization with an intact immunoglobulin and usually recognizes idiotypic antigenic determinants as a result of a particular quaternary interaction of the light and heavy chains. The antigenic site recognized by this group of anti-idiotype antibodies, however, is not associated with a particular light or heavy chain amino acid sequence. Because the antibody binding site bears the internal image of the antigen; i.e., mimics the size, shape, charge and/or van der aals attraction the antigen, this group of anti-idiotype antibody binds to many different antibodies of the same specificity. The idiotypes recognized by such antibodies can be produced by individuals with different genetic backgrounds and are controlled by genes that bear no special relationship. Anti-idiotype immunotherapy can be very useful in the treatment of autoimmune disease, by neutralizing pathological auto-antibodies. Moreover, anti-idiotye iπύnunotherapy can be used in the treatment of certain B cell malignancies. Current therapeutic techniques in this area include chemotherapy, active immunization with non-specific stimulants of the immune system and passive immunization with antibodies directed against specific markers including idiotypes. The major disadvantage of the first two techniques is the lack of specificity which, in the case of chemotherapy, usually results in general tissue toxicity. On the other hand, anti-idiotypic therapy can be highly specific. But such therapy suffers from the disadvantages associated with passive administration since the anti-idiotype antibodies must be produced in a non-human species. Therefore, a significant possibility exists that an individual so treated will develop an immune response against the passively administered antibodies, which response can negate any potential therapeutic effect. This is particularly true because the antibodies must be administered many times to produce the desired result. Moreover, all anti-idiotype antibodies have previously been generated by immunizing the host with the target immunoglobulin. The resulting polyclonal antisera must then be extensively purified to produce antibodies having the desired anti-idiotype specificity. The selected, purified, "monoclonal" antibodies must then be carefully tested to determine their specificities. The structural correlates of idiotypes have been sought in several well-defined antibody systems. See Kunkel et al. , Science, 140, 1218 (1963); Capra et al. , Proc. Natl. Acad. Sci. USA, 71, 4032 ^ (1974); Weigert et al. , J. Exp. Med., 139, 137 (1974) ; Klapper et al. , Ann. Immunol. (Inst. Pasteur) , 127C, 261 (1976); Schilling et al. , Nature, 283, 35 (1980) ; Capra et al.., Immunol. Today, 3_, 332 (1982); and Capra et al. , Immunol. Today, , 177 (1983) . These studies suggest that a hypervariable region (also referred to as a complementarity- determining region or a CDR) of an immunoglobulin is the structural correlate of an idiotypic determinant. In particular, in the murine anti-dextran system, one private (or individual) idiotype and one public (or cross-reactive) idiotype were assigned to the third and second hypervariable regions, respectively, of the heavy chain. Schilling et al. , supra. However, in most systems, it has proven extremely difficult to associate a particular idiotypic determinant with a specific amino acid sequence, Capra et al. , Immunol. Today, , supra. Rather, anti-idiotypic antibodies elicited by . immunization- with an intact immunoglobulin usually recognize determinants dependent upon a particular quaternary interaction or "internal image" of both of the light and heavy chains Capra et al. , Id. erner et al. have been successful in obtaining protection of animals by the use of vaccines against pathogens that utilize synthetic polypeptides having amino acid residue sequences of short to moderate length as immunogens. See Sutcliffe et al. , Science, 219, 495 (1983) . Such synthetic polypeptides induce antibodies specific for predefined determinants of intact proteins. As described herein, synthetic polypeptide technology can avoid the previously described difficulties associated with conventional anti-idiotype therapy. According to the present invention, described in detail hereinafter, polypeptides having relatively short amino acid residue sequences that substantially correspond to the portion of the immunoglobulin primary sequence that forms the idiotype can be synthesized, coupled to an appropriate carrier and inoculated into animal hosts including humans as immunogens to raise antibodies. The resulting antisera recognize the immunoglobulin(to a portion of which the polypeptide corresponds in amino acid residue sequence)and are idiotype specific. Such antisera produced by synthetic polypeptides are thus of predetermined specificity and the necessity for extensive purification and specificity testing is eliminated. In addition, such synthetic polypeptides alone, as conjugates or as polymers can be administered to individuals to raise antibodies that immunoreact with the particular idiotypes of that individual. Autologous anti-idiotype antibodies are well documented and are widely believed to be very important in im unoregulation. One advantage in the use of synthetic polypeptide-containing antigens (immunogens) is that antibodies reactive with otherwise non-imraunogenic determinants can be elicited. Therefore, appropriate synthetic polypeptides can induce anti-idiotype antibodies in an individual that are directed against a particular idiotype of that individual whereas this could not be achieved by immunizing with the intact immunoglobulin. Thus, an individual can be actively immunized against a pathological idiotype and the number of therapeutic interventions required can be substantially reduced compared to conventional immunization with an intact immunoglobulin. Also, the possibility of an immune response against the anti-idiotype antibodies can be reduced substantially. Polypeptides can also be synthesized to mimic an antigen under attack by pathological auto-antibodies. These polypeptides can block or inhibit the interaction between the antigen and the undesired auto-antibodies, thereby significantly impeding the disease process. It is believed that certain idiotypes occur very frequently in particular syndromes. Synthetic polypeptides, corresponding to such idiotypes may be used to elicit antibodies of predetermined specificity for such syndromes, and may then be applied in the diagnosis of that syndrome. Brief Summary of the Invention The present invention contemplates the use of synthetic polypeptides to mimic idiotypic antigenic determinants on immunoglobulin molecules and to elicit the production of antibodies (anti-idiotype antibodies) of predetermined specificity which are reactive with those idiotypes. Such antibodies can be useful in the treatment of autoimmune disease and certain diseases of B-lymphocytes. Such antibodies can also be used in the diagnosis of disease where a particular idiotype occurs. A synthetic polypeptide in accordance with this invention has an amino acid residue sequence of contiguous amino acids that substantially corresponds iπununologically to the amino acid sequence of an idiotypic antigenic determinant; i.e., a variable or hypervariable region, of an immunoglobulin. The polypeptide contains from about 6 to about 40 amino acid residues and preferably from about 8 to about 20 amino acid residues. The polypeptide, when administered alone or as polymer or as a conjugate bound to a carrier such as keyhole limpet hemocyanin (KLH) or the like and introduced in an effective amount in a physiologically acceptable vehicle into a host animal, induces the production of anti-idiotypic antibodies in the host. Throughout the application, the terms "peptide" and "polypeptide" are used interchangeably. The term "synthetic polypeptide" means a chemically derived chain of amino acid residues that is free of naturally occurring proteins and fragments thereof. Such synthetic polypeptides can elicit production of anti-idiotype antibodies in a host. The phrase "immunologically corresponds substantially" in its various grammatical forms is used herein and in the claims in relation to polypeptidesequences to mean that the polypeptide sequence described induces production of antibodies that bind to the polypeptide as well as to the idiotypic antigenic determinant. The term "substantially corresponds" in its various grammatical forms is used herein and in the claims in relation to polypeptide sequences to mean the polypeptide sequence described plus or minus up to three amino acid residues at either or both of the amino- and carboxy-termini and containing only conservative substitutions in particular amino acid residues along the polypeptide sequence. The term "conservative substitution" as used above is meant to denote that one amino acid residue has been replaced by another, biologically similar residue. Examples of conservative substitutions include the substitution of one hydrophobic residue such as lie, Val, Leu or Met for another, or the substitution of one polar residue for another such as between Arg and Lys, between Glu and Asp or between Gin and Asn, and the like. In some instances, the replacement of an ionic residue by an oppositely charged ionic residue such as Asp by Lys has been termed conservative in the art in that those ionic groups are thought to merely provide solubility assistance. In general, however, since the replacements discussed herein are on relatively short synthetic polypeptide antigens, as compared to a whole protein, replacement of an ionic residue by another ionic residue of opposite charge is considered herein to be "radical replacement", as are replacements between nonionic and ionic residues, and bulky residues such as Phe, Tyr or Trp and less bulky residues such as Gly, lie and Val. The terms "nonionic" and "ionic" residues are used herein in their usual sense to mean those amino acid residues that normally either bear no charge or normally bear a charge, respectively, at physiological pH values. Exemplary nonionic residues include Thr and Gin, while exemplary ionic residues include Arg and Asp. According to the method of the present invention, a suitable host.is treated with an effective amount of a synthetic polypeptide in a physiologically acceptable vehicle, the polypeptide having an amino acid residue sequence that immunologically corresponds substantially to an amino acid sequence of a variable or hypervariable region (an idiotypic antigenic determinant) of an immunoglobulin. Anti-idiotype antibodies are thus produced which can bind to the variable or hypervariable region, respectively, of the immunoglobulin. In this manner, the resulting "anti-antibody" or "anti-idiotype antibody" has a predetermined specificity and has substantially the same configuration as an antigen that binds to the variable or hypervariable region of the immunoglobulin. Antibodies of.this type provide an improved means for defining the structure of idiotypes, as well as providing means for diagnostics and therapy. The method of the present invention produces antibodies against synthetic polypeptides that mimic an idiotypic antigenic determinant of a naturally occuring protein and result in a large fraction of -li¬ the elicited sera being reactive against the natural and the denatured protein. It remains unclear whether in a given anti-polypeptide serum the same antibody molecules are responsible for the interaction with both native and denatured proteins or whether different antibody molecules in the antiserum react preferentially with one or the other of the two protein states. Whether same or different antibodies react with the denatured and native proteins may depend on the characteristics of the particular epitope or idiotope being considered. Another aspect of this invention is that the method of producing antibodies against synthetic polypeptides can be used to raise antibodies against idiotypic antigenic determinants that are not naturally immunogenic in the host. That is, certain portions of a macromoleσule have the ability to be bound by an antibody (i.e., are antigenic) but do not elicit the production of antibodies (i.e., are not immunogenic) . Certain idiotopes are an example of such determinants which are antigenic but not immunogenic. Thus, the polypeptides of the present invention may be used to terminate tolerance and • thereby target the immune response to restricted regions of self-proteins. Anti-idiotype antibodies produced according to this invention have several distinct advantages over anti-idiotype antibodies produced by conventional immunization with an intact immunoglobulin. Conventional anti-idiotype sera distinguish . the idiotype on the basis of the quarternary structure of the immunoglobulin. That, is, the anti-idiotype antibody recognizes a thsee dimensional protein structure created by the folding of the primary sequence and the juxtalocation of non-contiguous regions of the primary sequence. Anti-idiotype antibodies produced according to this invention can distinguish idiotopes on the basis of continuous, sequence defined determinants. The recognition site does not require the juxtalocation on non-contiguous regions of the primary sequence. This results in an ability to generate anti-idiotype antibodies with a high degree of specificity to a predetermined region of the primary sequence. This was not possible with conventional methodology. Another advancement of this invention over conventional methodology is that anti-idiotype antibodies can be produced against a particular idiotype without the need for purification. Conventional techniques for raising anti-idiotype antibodies involves immunizing a host with the appropriate immunoglobulin ox a fragment thereof. This results in a polyclonal response against the various idiotypic antigenic determinants on the immunoglobulin. The sera must then be passed over an absorption column to separate and to isolate the particular anti-idiotope of interest, and to produce serum with specificity for an idiotype. In contrast, the present invention requires no absorption purification. By the method of this invention, highly specific anti-idiotype antibodies can be produced against a predetermined and predefined idiotype. Still further, synthetic polypeptide technology provides new analytical tools which may play a paramount role in answering questions about the structural correlates of idiotype. Anti-polypeptide antisera directed against certain idiotypic determinants located in the antigen binding regions of antibodies may be a way to relate protein structure to antigen binding. For example, one could induce a set of antibodies to different regions in the vicinity of the binding site and determine which perturb antigen-antibody union. The word "antigen" has been used historically to mean the entity that is bound by an antibody as well as to mean the entity that induces the production of the antibody. More current usage limits the meaning of antigen to that entity bound by an antibody, while the word "immunogen" is used for the entity that induces antibody production. In some instances, the antigen and immunogen are the same entity as where a synthetic polypeptide is utilized to induce production of antibodies that bind to the polypeptide. However, the same polypeptide can also be utilized to induce antibodies that also bind to a whole protein such as immunoglobulin, in which case the polypeptide is both immunogen and antigen, while the immunoglobulin is an antigen. Where an entity discussed herein is both immunogenic and antigenic, it will generally be termed an antigen. Brief Description of the Drawings In the drawings, which constitute a portion of this disclosure: Figure 1 illustrates the amino ' acid sequence of myeloma protein M104 from positions .90 to 110. The D-segment amino acids located at positions 100 and 101 are indicated in bold type. The line for the sequence of myeloma protein J558 indicates a similarity with the sequence of M104 except, as shown, for the D-segment. Polypeptides 3MN and 3JN have shorter amino acid sequences than the corresponding sequences of polypeptides hv3M and hV3J, respectively, but include additional amino acids shown in italics to space the sequence from the carrier protein and to increase solubility. Figure 2 shows nitrocellulose (Western) blots of sodium dodecyl sulfate (SDS)-polyacrylamide gels including anti-polypeptide sera. Lanes 1-12 illustrate the results obtained with the individual antisera generated as described with reference to Figure 1. Lane 13 shows the result with pooled, normal rabbit serum. Lane 14, on the other hand, shows the total protein in each lens. The upper lanes contain M104 myeloma protein and the lower lanes contain J558 myeloma protein. Electrophoresis was performed from top to bottom with 11 micrograms of protein being loaded per lane. Sera 1-8 and 13 were diluted 1 in 100 in a 1% by weight solution of powdered milk in borate buffered saline (BBS) [see Johnson et al. , "Improved Technique Utilizing Nonfat Dry Milk for Analysis of Proteins and Nucleic Acids Transferred to Nitrocellulose" , Gene Analysis Techniques (1983)] before use while sera 9-12 were diluted 1 in 10 in the same medium. The letters M and J indicate which protein sequence corresponds to the immunizing polypeptide (see Table 1 and Figure 1) . Figure 3 shows Western blots of non-dissociating gels probed with anti-polypeptide sera. The details are as described for Figure 2 except that 13 icrograms M104 protein and 14 micrograms J558 protein were loaded per lane. The bands of J558 protein at the top of the lower set of gel lanes indicate material which did not enter the resolving gel. This may comprise IgA (immunoglobulin A) dimers and perhaps higher oligomers. Figure 4 demonstrates the inhibition of the polypeptide-induced anti-idiotype antibody binding to the polypeptide (A) and to the intact IgM-RF (Sie; B) . Antibody binding was inhibited by: polypeptide ( • ) , IgM-RF (Sie ; ■ ) and control polypeptide ( 4 ) , at the indicated concentrations. Figure 5 comprises a Western blot of 5 monoclonal human rheumatoid factors and pooled human IgG, developed with separate polypeptide-induced anti-idiotype antisera from two immune rabbits (panels a and b) . Each antibody identifies primarily a band of about 70,000 daltons which corresponds to the heavy chain of IgM-RF (Sie) . Control studies with a polyvalent anti-heavy chain antibody indicate that the minor bands of lower molecular weight represented minor proteolytic degradation products of the heavy chain. The markers used are: fluoresceinated-bovine serum albumin (F-BSA; 68k) , fluoresceinated-gamma H chain (F-HC; 53k) , fluoresceinated L chain (F-LC; 28k) and L chain (25k) « Figure 6 identifies the amino acid residue sequences (corresponding to PSL2) of certain reported rheumatoid factors. The regions and residue numbers have been assigned by Rabat et al. , "Sequence of Proteins of Immunological Interest", U.S. Department of Health and Human Services (1983) . The public or cross-reactive idiotypes have been determined by Kunkel et al. , J. Exp. Med. , 137, 331 (1973). The amino acid rsidue sequences for IgM-RF (Sie) and IgM-RF (Wol) have been reported by Andrew et al. , Proc. Natl. Acad. Sci. USA, 78, 3799 (1981) , whereas the amino acid residue sequences for IgM-RF (Pon) and IgM-RF (Lay) have been reported by Klapper et al. , Ann. Immunol. (Inst. Pasteur) , 127C, 261 (1976) . Figure 7 is a Western ' blot analysis of the antibody activity of the anti-PSL2 antiserum. About 20 micrograms of each indicated sample were loaded on each gel. After electrophoresis on sodium dodecyl sulfate-polyacrylamide gel and electrophretical transfer to nitrocellulose paper, the samples were reacted respectively with anti-IgM (A, D) , anti-PSH3 (B) and anti-PSL2 (C, E) antisera. After subsequent development with the 125I-protein A (Staphylococcus aureus) , the papers were finally exposed to film overnight, except that (D) and (E) were exposed for three days. Figure 8 illustrate that PSL2 inhibits the binding of PSL2-induced antibodies to the IgM-RF (Sie) (panel A) ; and to the isolated light chains of RF-Glo (o; panel B) . In addition, inhibition by the control PSH3 { Λ ) is shown in panel B. Figure 9 illustrates inhibition of the IgM-RF Sie binding to the bound polypeptide-induced anti-idiotype antibody. The PSL2 and the control PSH3 were added at the indicated concentrations to wells precoated with affinity-purified anti-PSL2 antibodies. After incubation for one hour at room temperature (23°C) , AP-IgM-RF Sie (10 micrograms per milliliter) was added to each well and the plate was incubated for another 1.5 hours at room temperature. Thereafter, the plate was washed, and the absorbance at 405 nanometers was measured one hour after the addition of substrate to the wells. Detailed Description I. Introduction Idiotypic determinants are generally believed to be involved in immunoregulation as described by Jerne, Ann. Immonol. (Inst. Pasteur) , 1255, 373 (1974) and Binion et al. , J. Exp. Med., 156, 860 (1982) . Control of the system also appears to involve idiotype- specific T-cells as described by • Milburn et al. , J. Exp. Med., 155, 852 (1982) . Evidence shows that the predominant expression of certain idiotypes may be the result of a regulatory process rather than a restricted immunological repertoire as described by Casenza et al. , Immunological Rev. , 34, 3 (1977) . Since idiotype and anti-idiotype antibodies are involved in immune regulation, it is possible to manipulate the immune response by inducing autologous anti-idiotype antibodies as described in Cosenza et al. , supra. This manipulation with anti-idiotype antibodies is believed to have considerable medical significance in certain B-cell malignancies and autoimmune diseases. In those autoimmune diseases where the injurious antibody is of restricted origin, it may be possible to use. synthetic immunogens to modulate or even eliminate the B cell clones producing the antibody. Such autologous anti-idiotype antibodies to manipulate the immune response can be produced in an animal according to the method of the present invention. If a specific clonal type is sought to be regulated, then an anti-idiotype antibodies against a private iditope should be raised. But, a private idiotope is an idiotope found on only one or a few clones of an antibody of a given specificity. If regulation of all antibodies of a given specificity is sought, then anti-idiotype antibodies against a public idiotope should be raised. Anti-idiotype antibodies have a second mode of function to combat autoimmune diseases and transplant or graft regulations. For example, an anti-idiotype antibody may block or obstruct the binding site so as to preclude union between the injurious antibody and its antigen. An "antigenic determinant" is a portion of the structural configuration of macromolecule which has the capability to be bound by an antibody. Further explanation of an "antigenic determinant" is best accomplished by way of example. A simple protein is comprised of a linear chain of amino acid residues. This chain folds into a three dimensional structure. Certain portions of the chain are internal and other portions are external. In addition, amino acid residues that are distant apart in the primary sequence are brought into close proximity by the folding. A protein structural arrangement (configuration) thereby results. Certain portions of this configuration are such that they have the ability to be bound by an antibody of appropriate specifity; that is, they are antigenic determinants. These portions of the configuration can be thought of as having the right "shape", proper neighboring molecular environment, to bind an antibody. The antigenic determinants of particular interest in this invention are located in the idiotypic region of an immunoglobulin and are therefore termed idiotypic antigenic determinants. The presence of an antigenic determinant on a molecule is not limited to simple proteins. The ability is general to most natural macromolecules which include, for example, glycoprqteins, dextrans, multipolypeptide chain proteins and the like. The word "immunogenic" is used to describe the ability of an antigenic determinant to elicit an immune response; i.e., initiate production of antibodies against the determinant. Not all antigenic determinants are immunogenic, as noted generally before. This is ' so because of several reasons. First, the animal may have tolerance to the antigenic determinant. Second, the molecular environment around the determinant may not be right for eliciting antibody production. Third, there may be certain factors in the sera that inhibit antibody production, for example, shedded "tumor specific transplantation antigens". The antigen binding site of an immunoglobulin is, in many respects, no different from any other macromolecule. Thus, the present invention illustrates that with respect to antigenicity and immunogenicity, portions of the structural configuration of the binding site and of the surrounding region can be antigenic and immunogenic. Such antigenic determiants found in the region of the binding site are called idiotopes. Often, a binding site region will have several idiotopes. As explained earlier, "idiotype" is the term used to describe the set of idiotopes expressed in a binding site region. Idiotopes have been shown to be found in the pocket of the- binding site and on the surrounding surface. This finding has been confirmed by x-ray diffraction techniques conducted by Givol, Int. Review of Biochem, 23, 71 (197-9) . Studies of idiotopes have revealed that idiotopes lend themselves to be classified into two natural categories. In 1968, Williams showed that antibodies with similar binding specifities possessed idiotopes unique to themselves as well as idiotopes which they shared with the other antibodies of the same specifity. A study by Schilling et al. , Nature, 283, 35 (1980) involved 10 hybridoma clones and three myeloma proteins against alpha-l,3-dextran. This study revealed that more than one half the anti- dextran antibodies shared an idiotope. The study also revealed idiotypes unique to one or a few clones. Idiotypes thus lend themselves to classi¬ fication into two catagories based on this phenomenon. The first category of idiotope is the "cross-reactive" or "public" idiotope. Th.e cross-reactive idiotope is an idiotope shared by several antibodies of the same specifity. Antibodies to a given antigen generated in different strains of the same species or even different species have been shown to possess the same idiotope. The second category of idiotope is the "private" or "individual" idiotope. This idiotope is found on only one of a few clones of the antibodies to a given antigen. Changes in the amino acid composition of an idiotope do not necessarily change the binding site specificity. Rajewsky et al. , Ann. Rev. Immunol. , 1 , 569 (1983) . A single amino acid change in the D gene segment led to loss of one idiotype, modification of a second and loss of six others in the parent molecule. However, the antibody still retained its binding site specifity. This finding even applied if the idiotope was located in or near binding site pocket. On a final note, an animal has over one million antibodies of different binding site specifities. Associated with each binding site specifity is a set of idiotopes. Thus in an animal there is an enormous number of idiotopes. The present invention employs the technology of raising antibodies against naturally occurring aminal proteins using short chemically syntheszed polypeptides. The basic scheme of this technology is as follows. To begin, the primary sequence of a protein or a portion thereof is determined. This is accomplished by one of several ways. First, the sequence information may have already been determined and is available from the literature. Second, the protein itself can be isolated and directly sequenced, using methods well known in the art. Third, the gene which codes for the protein can be identified using genetic techniques well known in the art. The identified gene can then be cloned and isolated using recombinant DNA technology. The primary sequence of the protein can be determined from the cloned gene in either of two ways. First, the gene itself can be directly sequenced and this information translated into primary sequence, all using techniques and information well known in the art. Second, the protein coded from the gene can be sequenced. The next step after determining the primary sequence is to analyze the sequence for regions included in antigenic determinants. This is accomplished using the general knowledge of biochemistry and immunology and specific information on the behavior of the particular protein. Next, short polypeptide portions of the regions associated with an idiotypic antigenic determinant are chemically synthesized using methods such as those described in Merrified et al. , J. Amer. Chem. Society, 86, 2149 (1963) . The chemically synthesized polypeptide is typically bound to a carrier as a conjugate and the conjugate is injected in an effective amount as a vaccine into a host animal. Antisera are raised against the conjugate in which the. specific antigenic determinant is the synthetic polypeptide. The present invention provides a method for producing antisera specific for a defined idiotype of an antibody using synthetic polypeptides. That is, through use of the present invention, synthetic polypeptide technology can be employed to produce anti-idiotype antibodies. The antibodies formed have at least the following characteristics. First, the antibodies have the capability of 5 distinguishing immunizing polypeptides and determinants on natural proteins (idiotypes) whose corresponding sequences differ by only two amino acid residues. Second, antibodies can be raised to a predetermined specific idiotype. This has not 10 previously been possible. Furthermore, antisera can be raised against idiotypes that are not naturally immunogenic in the animal. That is, the idiotype has the capability of being bound by an antibody (i.e. is antigenic) but 15 does not initiate antibody production against itself (i.e. is not immunogenic). Fourth, the antisera have the capability of reacting with both the natural and denatured protein. Fifth, a anti-idiotype sera can be generated without need for absorption. 20 . One of the uses and benefits of anti-idiotype antibodies is a possible means of medicinal immunoregulation. Immunoregulation using anti-idiotype antibodies and the reasoning behind selecting individual idiotypes will be discussed in 25 greater detail below. It will be understood that while there are many procedural steps utilizing many materials in the manufacture of the vaccines and anti-idiotype antibody preparations of this invention, as discussed 30 in detail hereinafter, the invention is not limited to the utilization of any particular steps or reagents or conditions, but rather the invention is conceptually as stated above and as defined with particularity in the claims appended hereto. ' 35 II. Peptide Syntheses and Selection A. Syntheses Polypeptides were synthesized by solid phase methods as described in Merrifield et al. , J. Amer. Chem. Soc. , 85, 2149 (1963) and Houghten et al. , Int. J. Peptide Protein Res. , 16, 311 (1930) . The relatively short polypeptides used herein substantially correspond to the hypervariable regions of selected immunoglobulin molecules. [Also see, Marglin et al. , Ann. Rev. Biochem. , 39, 841 (1970).] The polypeptides were coupled to the protein carrier KLH through a cysteine residue which was added to the carboxy-terminus of the polypeptide. The step of linking the polypeptide to the protein carrier was performed by addition of the cysteine sulfur atom to the double bond of the reaction product between the carrier and N-maleimidobenzoyl-N-hydroxy succinimide ester (MBS) , following the procedure described by Liu et al. , Biochemistry, 18, 690-697 (1979) . B. Polypeptides Related to M104 and J558 Proteins A myeloma protein is simply an antibody produced by a B-cell which has undergone a transformation to a cancer-causing cell. It is essentially the same as an antibody produced by a normal healthy B-cell. M104 and J558 are myeloma proteins produced by the MOPC104E and J558 murine myelomas. Like any antibody, they have a binding site specificity. These antibodies bind the alpha-l,3-glycoside linkage of B1355 dextran. Leon et al. r Biochemistry, 9_, 1023-1030 (1982) and Londblad et al. , Immunochemistry, 9_, 535,544 (1972). Both the heavy and the light chains of M104 and J58 myeloma proteins have been sequenced. The light chains of both myeloma proteins are of the lambda allotype and are identical in sequence. Appella, Proc. Natl. Acad. Sci. USA, 68, 540-544 (1971) and Weigert et al. , Nature, 228, 1045-1047 (1970) . The heavy chain variable regions of both myeloma proteins have identical sequences throughout the variable domain except for the D-segment in the middle of the third hypervariable region. It is to be noted that the M104 myeloma is a mu isotype and the J558 is an alpha isotype. Kehry et al. , Proc. Natl. Acad. Sci. USA, 76, 2932-2936 (1979) and Schilling et al. , Nature, 283, 35-40 (1980). The D segment sequences have been shown to determine an "individual idiotype" expressed by the M104 and J558 myeloma proteins. Clevinger et al. , ICN-UCLA Symp. Molec. Cell. Biol. , 3 , 159-168 (1981) . An additional idiotype, determined by amino acids at positions 54 and 55 in the heavy chain, is expressed by both M104 and J558 myelomas and also by most of the clonotypes elicited by Dextran B1355 in the Balb/c mouse. Clevinger et al. (1981) supra, Clevinger et al. , J. Exp. Med. , 151, 1059-1070 (1980), and Blomberg et al. , Science, 177, 179-189 (1972) . The light chains of the M104 and J558 are identical in sequence. The heavy chain variable regions are identical except for the D segment. Thus it appears that the individual idiotype found in the third hypervariable region is determined by the heavy chain. Notwithstanding, this does not imply that the light chain does not play a role in the expression of the idiotype. The light chain may be required to stabilize the conformation of the determinant. Carson et al. , Proc. Natl. Acad. Sci. USA, 70, 235-239 (1973) . Several synthetic polypeptides were used to induce the production of antibodies specific to a particular idiotype. In particular, an idiotype comprising the D segment of the third hypervariable region of M104 and J558 myeloma proteins was investigated. The D segment is comprised of two amino acid residues located at positions 100 and 101 from the amino-terminus. The D segment is bordered on the- amino-terminal side by the V segment and on the carboxy-terminal side by the J segment (see Figure 1) . Two sets of two synthetic polypeptides were prepared in this study. The first set comprised two polypeptides corresponding in sequence to the first seven adjacent amino acid residues in the J segment and 3 adjacent amino acids in the V segment of M104 and J558. These synthetic po.lypeptides were designed to be long enough, to ensure eliciting an anti-polypeptide immune response. The synthetic polypeptides were designated hV3M and hV3J and corresponded, respectively, to the above-described portions of the M104 and J558 myeloma proteins. The hV3M and hV3J polypeptides represent a substantial portion of the sequence encoded by the Jl gene segment which is common to both polypeptides. Thus, there was the possibility that much of the anti-polypeptide response would be directed against this common sequence. This could perhaps result in antibody activity specific for the different D-segments being obscured. The second set of synthetic polypeptides employed in this study included about a minimum cognate sequence necessary to form an antigenic: determinant as described by Lerner et al. , Nature, 299, 592 (1982) . These synthetic polypeptides were designated 3MN and 3JN corresponding, respectively, to the M104 and J558 myeloma proteins, and are shown in Figure 1, herein. In order to prevent steric interference with the immune presentation of the second set of polypeptide antigens with the carrier, three proline residues were added as a spacer between the cognate sequence and the KLH carrier protein. Proline, glycine and other groups have been used successfully as spacers as described in Stevens et al. , Am. J. Reprod. Immunol, 1 , 307 (1981) . Glutamic acid residues were added to the sequence to increase solubility. C. Polypeptides Related to IgM-RF For the most part, antibody response is directed against invading organisms and altered self cells or self antigens. For example, rheumatoid factor (RF) is an IgM or IgG antibody with specificity for the Fc fragment of IgG. Rheumatoid factor usually results from an abnormal condition and causes synovial inflamation and vascolitis. IgM-RF is abundant in the sera of most individuals with rheumatoid arthritis. IgM-RFs in rheumatoid sera are polyclonal and react with a number of different antigenic determinants in the Fc region of IgG. IgM-RFs from unrelated individuals show cross-reactive idiotypes. A polypeptide (designated PSH3) was synthe¬ sized that corresponded to the third hypervariable region (amino acid residues 99-111) of the heavy chain of the monoclonal IgM-RF (Sie) antibody according to the sequence reported by Andrews et .al. , Proc. Natl. Acad. Sci. USA, 78, 3799 (1981) . The polypeptide had the sequence from left to right and in the direction from amino-terminus to carboxy- terminus of: GluTrpLysGlyGlnValAsnValAsnProPheAspTyr. A tripeptide GlyGlyCys was added to the carboxy-terminal (C-terminal) end of the above polypeptide sequence to facilitate coupling to a protein carrier as described by Green et al. , Cell, 28, 477 (1982) . The resulting polypeptide had the following sequence from left to right and in the direction from amino-terminus to carboxy-terminus: GluTrpLysGlyGlnValAsnValAsnProPheAspTyrGlyGlyCys. A polypeptide (designated PSL2) was synthe¬ sized that corresponded to the second hypervariable region (amino acid residues 49-61) of the L chain of the monoclonal IgM-RF (Sie) , according to the sequence reported by Andrews et al. , supra. PSL2 has the amino acid residue sequence from left to right and in the direction from amino-terminus to carboxy-terminus of: TyrGlyAlaSerArgAlaThrGlylleProAspArg. An additional Cys was added to the C-terminal end of the sequence to facilitate coupling to the protein carrier as referenced above. III. Immunization Procedures The vaccines used herein contain the stated amount of polypeptide alone, as a polymer of individual polypeptides linked together through reaction with glutaraldehyde or linked to a carrier. Polymeric polypeptides can also be prepared by addition of cysteine residues at both polypeptide termini followed by oxidation as with atmospheric oxygen at moderate pH values such as between about pH 7 and pH 10. The stated amounts of polypeptides refer to the weight of polypeptide without the weight of a carrier, when a carrier was used. The vaccines also contained a physiologically acceptable vehicle such as water or saline, and further typically included an adjuvant. Complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant (IFA) are materials well known in the art and are available commercially from several sources. Vaccine stock solutions were prepared with IFA or CFA as follows. An amount of the synthetic polypeptide, polymeric polypeptide or conjugate sufficient to provide the desired amount of polypeptide per inoculation was dissolved in borate-buffered saline (BBS) . Equal volumes of CFA or IFA were then mixed with the polypeptide solution to provide a vaccine containing polypeptide, water and adjuvant in which the water-to-oil ratio was 1:1. The mixture was thereafter homogenized to provide the vaccine stock solution. Vaccine stock solutions can also be prepared with keyhole limpet hemocyanin (KLH) , KLH in IFA . (incomplete Freund's adjuvant), alum, KLH-alum ' absorbed, KLH-alum absorbed-pertussis, edestin, thyroglobulin, tetanus toxoid and tetanus toxoid in IFA. Upon injection or Qther introduction of the antigen or vaccine into the host, the host.'s system responds by producing f large amounts of antibody to the antigen. Since the specific idiotypic antigenic determinant of the manufactured antigen, i.e., the antigen formed from the synthetic polypeptide and the carrier, is the same as or is an immunological surrogate for the determinant of the natural antigen of interest, the host becomes immune to the natural antigen. In the case where the invention is used as a vaccine, this is the desired result. The effective amount of polypeptide per inoculation (as discussed in the accompanying tables) depends, inter alia, on the animals inoculated, body weight of such animals and the chosen inoculation regimen. Vaccines are typically prepared from the dried solid polypeptide by suspending the polypeptide in water, saline or adjuvant, or by binding the polypeptide to a carrier and suspending the carrier-bound polypeptide (conjugate) in a similar physiologically tolerable vehicle such as an adjuvant. An effective amount of polypeptide present in a vaccine may be from about 20 micrograms to about 500 milligrams per inoculation, exclusive of any carrier used. It is frequently convenient to add one or more additional amino acids to the amino- or carboxy-termini of the synthetic polypeptide to assist in binding the synthetic polypeptide. to a carrier to form a conjugate. As discussed before, cysteine residues added at the carboxy-terminus of the synthetic polypeptide have been found to be particularly useful for forming conjugates via disulfide bonds and Michael addition reaction products, but other methods well known in the art for preparing conjugates may be used. Exemplary binding procedures include the use of dialdehydes such as glutaraldehyde and the like, or the use of carbodiimide technology as in the use of a water-soluble carbodiimide, e.g. l-ethyl-3- (3-dimethylaminopropyl) carbodiimide. Useful carriers are well known in the art and are generally proteins themselves. Exemplary of such carriers are keyhole limpet hemocyanin (KLH) , edestin, thyroglobulin, albumins such as bovine serum albumin or human serum albumin (BSA or HSA, respectively) , red blood cells such as sheep erythrocytes (SRBC) , tetanus toxoid, as well as polyamino acids such as poly(D-lysine:D-glutamic acid) , and the like. As is also well known in the art, it is often beneficial to bind the synthetic polypeptide to its carrier by means of an intermediate, linking group. As noted above, glutaraldehyde is one such linking group, while when cysteine is utilized, the intermediate linking group is preferably a m-maleimidobenzoyl N-hydroxysuccinimide ester (MBS) . MBS is typically first added to the carrier by an ester-amide interchange reaction. Thereafter, the above Michael reaction may be followed, or the addition may be followed by addition of a blocked mercapto group such as thiolacetic acid (CH 3 COSH) across the maleimido-double bond. Cleavage of the blocking group follows, and then the disulfide bond is formed between the deblocked linking group mercaptan and the mercaptan of the added cysteine residue of the synthetic polypeptide. The choice of carrier is more dependent upon the ultimate intended use of the antigen than upon the determinant of the antigen, and is based upon criteria not particularly involved in the present invention. For example, if a vaccine is to be used in animals, a carrier which does not generate an untoward reaction in the particular animal will be selected. If a vaccine is to be used in man, then the overriding matters relate to lack of immunoσhemical or other side reaction of the carrier and/or the resulting antigen, safety and efficacy—the same considerations which apply to any vaccine intended for human use. It is very often desirable to determine if a particular antigen is present as an aid, for example, in the diagnosis of a particular disease. Because the synthetic antigen is mono-specific to the single specific antigenic determinant of interest, antibodies to the antigen are also mono-specific to the antigen of interest. Perfect mono-specificity may not always be accomplished but cross-referencing to other antigenic portions of the antigen is avoided because only one immune response is possible by the antibody. Antibodies are harvested and prepared in any conventional procedure for use in diagnostic tests. It is common, for example, to label the antibody for identification and quantitative determination. Radiolabelling by the method of Greenwood, for example, [See Hunter, Br. Med. Bull. 30,18 (1974)] and fluorescent dye labelling are commonly used in immunoassays. Vaccines are prepared by suspending the carrier-bound (conjugate) polypeptide in a physiologically tolerable vehicle. Other acceptable suspension media are well known in the art and include water, saline, and the like. The suspended carrier-coupled synthetic polypeptide will be referred to herein as a vaccine. IV. Results A. Immunization With M104 and J550 Related Polypeptides The vaccines were injected into host animals in an effective amount to elicit an immune response. Three immunization procedures were employed to generate anti-polypeptide sera against the polypeptides as described in Table 1. Two rabbits were taken through the immunization process for each synthetic polypeptide. Antisera against the hV3M and hV3J polypeptide were raised in New Zealand white rabbits and antisera against the 3MN and 3JN polypeptides were raised in red New Zealand Rabbits. Table 1 " 1. The various immunization protocols employed to generate the anti-polypeptide sera using synthetic polypeptides related to myeloma proteins Ml04 and J558 are shown. Rabbits 1-8 were female New Zealand White and rabbits 9-12 were female New Zealand Red. Each animal received 200 micrograms peptide coupled to KLH at each injection. Rabbits 1-8 were bled 7 days after the last injection and rabbits were bled 9 days after the last injection. 2. The adjuvant used and the injection sites are shown for each injection. The following abbreviations are used: CFA - complete Freund's adjuvant; IFA - incomplete Freund's adjuvant; sc - 4-8 multiple subcutaneous injections in the back; fp - injection into both rear footpads; lfp or rfp - injection into one rear footpad, left or right, respectively; and ip - intraperitoneal injection. 3. Intervals between successive injections are shown in days. The immunization procedures involved either three or four innoculations of vaccine. In any inoculation, the animal received two hundred (200) micrograms of synthetic polypeptide coupled to keyhole limpet hemocyanin (KLH) and the conjugate was either emulsified in Freund's adjuvant or alum. The vaccines were administered in either multiple subcutaneous injections in the back and rear footpads or intraperitoneally. Subsequent inoculations followed between 7 and 62 days after the prior inoculation. The rabbits immunized with HU3J and hV3M polypeptides were bled 7 days after the last inoculation and the rabbits immunized with 3MN and 3JN polypeptide were bled 9 days after the last inoculation. 1. Reactivity with denatured M104 and J558 proteins The antisera were first evaluated for their ability to descriminate between denatured M104 and J558 myeloma proteins. The determination was accomplished by first running M104 and J558 myeloma proteins on vertical slab denaturing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using a five to ten percent polyacrylamide gradient as described in Laemnli, Nature, 227, 680 (1970) . The proteins were then electrophoretically transferred to nitrocellulose (Schleider and Shuell Inc., of Keene, NH) as described in Towbin et al. , Proc. Natl. Acad. Sci. USA, 76, 4350 (1979) . Next, the blots were stained with amino black and were cut into strips corresponding to the gel lanes. Non-specific binding was blocked with a reagent recently devised for this purpose as described in Johnson et al. , supra. Finally, the strips were exposed to. anti-polypeptide sera for two hours at room temperature and positive reactions were then visualized with I 125 - Protein A (Staphylococcus aureus) and autoradiography as described in Johnson et al., supra. The results of this determination are illustrated in Figure 2. Two rows of a plurality of strips are shown. The top row of strips illustrates binding of the various antisera to the denatured M104 protein. The bottom row illustrates binding of the various antisera to the J588 protein. Fourteen columns of strips are illustrated. Each column is labeled with a number at the top. Columns 1 through 12 correspond to antisera raised in the twelve immunized rabbits, respectively (Table 1) . Column thirteen in a blank and column fourteen is a standard showing the migration positions of the myeloma protein. Below the column number is the letter M or the letter J. The letter M indicates that the rabbit was immunized with a polypeptide containing the D segment of a M104 myeloma protein. The J indicates that the rabbit was immunized with a polypeptide containing the D segment of . a J558 myeloma protein. The antisera raised in eight of the twelve rabbits (Numbers 1, 3, 5, 6, 7, 8, 10, and 11) descriminated between the M104- and J558 proteins and displayed a high level of specificity for the protein corresponding to the immunizing polypeptide. Furthermore most, if not all, of the reactivity was confined to the heavy chain bands. This is consistent with the predetermined specificity of the anti-polypeptide sera. The faint additional bands which are apparent in lanes 1 and 6 are presumably due to either breakdown products or differences in glycosylation or both. Antisera raised against the hV3M and hV3J polypeptides in Rabbits 1, 2, 3, and 7 displayed cross reactivity between the two myeloma proteins. This cross reactivity is presumed to be due to extensive stretch of Jl gene segment sequence shared by both proteins. Attention is also called to the observation that the antisera raised in rabbits 9 and 11 did not react with the denatured M104 myeloma proteins. The next section discusses a determination of the reactivity of antisera to the native myeloma proteins. There it will be shown that anti-sera raised in rabbits 9 and 11 react with the native. M104. These two observations coupled together tend to indicate that different antibody molecules in the antiserum react preferentially with or the other of the two protein states. This finding will be more thoroughly discussed in the next section. 2. Reactivity of the Anti-sera With Native M104 and J558 Proteins The antisera were evaluated for their ability to descriminate between native M104 and J558 myeloma proteins. This determination was accomplished by first running M104 and J558 myeloma proteins on vertical slab gel electrophoresis. The same apparatus was used as in the determination with denaturing gels. The following gel systems were employed: 1. M104 protein was run on a 7 percent agarose gel in a buffer gradient of 10 millimolar to 100 millimolar tris-borate pH 9.0 for 2.5 hours at 3 milli-amps. 2. The J558 protein was run in a 5 to 12 percent polyacrylamide gradient in 70 millimolar tris-borate pH 9.0 for 2 hours at 10 milli-amps. The proteins were transferred to nitrocellulose (Schleider and Shuell) , for the non-dissociating gels by way of a Bio-Rad (Richmond, CA) Trans-Blot cell utilizing seventy millimolar Tris-borate pH 9.0 as the transfer buffer. Next, the blots were stained with amido black, and were then cut into strips corresponding to gel lanes. Non-specific binding was blocked with a reagent described in Johnson et al. , supra. Finally, the strips were exposed to anti-polypeptide sera for two hours at room temperature and positive reactions were then visualized with I 125 - Protein A and autoradiography as described in Johnson et al. , supra. The results of this determination are illustrated in Figure 3. Two rows of a plurality of strips are shown. The top row of strips illustrates binding of the various antisera to the native M104 protein. The bottom row illustrates binding of the various anti-sera to the native J558 protein. The column number designations and immunizing polypeptide designations (M or J) are the same as that described in Figure 2. The bands in Figure 3 are more diffuse than those in the denaturing gel system (Figure 2) . This is because of an absence of stacking forces in the non-denaturing gels of Figure 3. The denaturing gels showed that the protein preparations used contained little, if any, extraneous protein material. Therefore, despite the diffuse appearance of the bands, the bands in Figure 3 comprise just M104 or J558 protein. The antisera raised in six of the twelve rabbits (numbers 1, 5, 6, 8, 9, and 10) descriminated between the M104 and J558 native protein and displayed specifity for the protein corresponding to the immunizing polypeptide. It is to be recalled that the antisera raised in rabbits 1, 3, 5, 6, 7, 8, 10, 11 demonstrated the same abilities with respect to the denatured protein. Thus, at least half of the animals produced antibodies capable of descriminating the individual idiotypes of the M104 and J558 proteins, irrespective of whether the proteins were native or denatured. These results represent the first production of antibodies specific for defined idiotype elicited by synthetic immunogens. The antiserum raised in rabbit 9, and to a lesser extent the antiserum raised in rabbit 11, reacted with the native myeloma protein. However, the antiserum from these rabbits did not react with the denatured proteins (Figure 2) . It remains unclear whether, in the given anti-polypeptide serum, the same antibody-molecules are responsible for the interaction with both native and denatured proteins or whether different molecules in the antiserum react preferentially with one or the other or the two protein states. The precise situation may well depend on the particular epitopes being considered. The above data tends to indicate that different antibody molecules may be involved. Antisera raised against the hV3M-- and hV3J polypeptides in rabbits 1, 2, 3, 6, and 7 displayed cross reactivity between the two myeloma proteins. This cross reactivity is presumed to be due to the extensive stretch of J gene segment sequence shared by both proteins. B. Immunization with IgM-RF Related Polypeptides 1. Immunizations Synthetic.polypeptides PSL2 and PSH3 were conjugated in sepa ate reactions via their terminal cysteines to keyhole limpet hemocyanin (KLH) with m-maleimidobenzoyl N-hydroxysuccinamide ester, as described previously. Green et al. , Cell, 28, 477 (1982) and Liu et al. , Biochemistry, 18, 690 (1979). Each of two rabbits was injected subcutaneously with 2.5 mg (milligrams) of the conjugates emulsified in complete Freund's adjuvant. The injection was repeated two months later. Three weeks after the second immunization, the rabbits were boosted again with 2.5 mg glutaraldehyde cross-linked polypeptide in incomplete Freund's adjuvant. The latter reagent was prepared by the addition of glutaraldehyde (final concentration 0.25 % v/v) to a 5 mg/ml solution of • polypeptide in isotonic phosphate buffered saline, followed by 1-hour incubation at room temperature, the rabbits were bled, and the sera were stored at 20°C until analyzed. 2. Purification of Proteins Plasma or purified proteins from patients with monclonal IgM cryoglobulins were purified by repeated precipitation at 4°C, followed by chromatography on Sephadex G-200 or Ultrogel AcA 22 in 0.2 molar sodium acetate at pH 3.5. IgM and IgG peaks were identified by immunodiffusion, and then the appropriate fractions were pooled and stored at a temperature of -20°C. Human IgG was prepared from Cohn fraction II (Sigma, St. Louis, MO) by DEAE cellulose chromatography in 0.01 molar sodium phosphate at pH 8.0. The heavy and light chains of the IgM-RF protein Sie were separated on a Sephadex G-100 column with 1 molar acetic acid, after complete reduction and alkylation. Bridges et al. , Biochemistry, 10, 2525 (1971) . The polypeptides were stored frozen at 1 mg/ml. Using a radioimmunoassay specific for IgM heavy chains or kappa chains, it was estimated that the heavy chains contained less than 5% light chains, while the light chains contained less that 2% heavy chains. 3. Enzyme Linked Immunosorbent Assay (ELISA) The synthetic polypeptide (100 micrograms/ml) , various purified monclonal IgM-RF (10 micrograms/ml) , and isolated heavy and light chains from the IgM-RF proteins (10 micrograms/ml) were dissolved in borate buffered saline (BBS) including 0.1 molar borate and 0.2 molar NaCl at pH 8.2. The mixture was then added to wells of polyvinyl chloride microtiter plates (Costar #3590) at a concentration of about 100 microliters per well. After overnight incubation at 4°C. , the plates were washed twice with BBS containing 0.5% Tween-20 (Sigma #P-1379; BBS/Tween-20) and were quenched with BBS containing 1% bovine serum albumin (BSA) " for one hour at room temperature. Then, 100 microliters of sera diluted with BBS containing 0.5% BSA were distributed to wells in duplicate. The plates were incubated for 3 hours at room temperature. Subsequently, each well was washed 3 times with BBS/Tween-20. Then, 100 microliter aliquots of a 1:800 dilution of alkaline-phosphatase labeled goat anti-rabbit IgG (Kirkegaard and Perry, Gaithersburg, MD) , that had been previously adsorbed with human IgG-Sepharose 4B, were dispensed to the wells. After another one hour incubation at room temperature, the plates were washed 5 times with BBS/Tween-20. Thereafter, 100 microliters of p_-nitrophenyl phosphate (1 mg/ml) in 0.05 molar sodium carbonate pH 9.8 was added to the wells, and the absorption at 405 nanometers was measured in a Titertek Multiscan meter after one hour at room temperature, and 16 hours at 4°C. 4. Inhibition Assay The inhibition of the anti-polypeptide antibody binding to plates coated with IgM-RF (Sie) or the polypeptide was assessed by the previously described ELISA methods, but with the following modifications. The antiserum from rabbit number 2 diluted 1:1,000 in BBS/0.5% BSA, was first mixed with an equal volume of inhibitors (e.g., Sie, immunizing polypeptide, or control polypeptide) at the concentration specified in Figure 1, and then was distributed to wells in duplicate 100 microliter aliquots. A polypeptide corresponding to the third hypervariable region of the heavy chain of the monoclonal human IgM-RF (Wol) having the amino acid residue sequence from left to right and in the direction from amino-terminus to carboxy-terminus of: GluTyrGlyPheAspThrSerAspTyrTyrTyrTyrTyrGlyGlyCys was used as a control. Andrews et al. , supra. 5. Adsorption and Elution of the IgM-RF (Sie) -binding activity The globulin fraction of anti-polypeptide antisera was precipitated twice with 40% ammonium sulfate, and then was digested with 3% (w/w) pepsin for 16 hours at 37 β C and pH 4.1. After neutraliza- tion, the digest was recirculated over a protein-A Sepharose 4B column (Pharmacia ' Fine Chemicals, Piscattaway, NJ) to remove undigested IgG. Subse¬ quently, the F(ab') 2 fragments were recirculated over a polypeptide-coupled Sepharose 4B affinity column (ca. 6.6 mg/ml gel x 5 ml), that had been prepared with cyanogen bromide activated Sepharose-4B (Sigma, St. Louis, MO) . After removal of non-bound • material with BBS the F(ab') 2 antipolypeptide antibody was eluted with 0.1 molar glycine HC1, pH 3.0, and was then dialyzed against BBS. -42- 6. Protein Blotting The reactivity of the anti-polypeptide antibody with immunoglobulin light and heavy chain polypeptides was tested by the Western blot method (Towbin et al. , Proc. Natl. Acad. Sci. USA, 76, 4350 (1979) as modified by Billings, et al. , J. Immunol. , 128, 1176 (1982) . Briefly, about 20 micrograms of individual monoclonal IgM-RF proteins [as discussed in Carson et al. , Mol. Immunol., 20, 1081 (1983)] or pooled human IgG in 25 microliters of sample buffer supplemented with 0.01% 2-mercaptoethanol, was loaded onto each slot of a 10% polycacrylamide slab gel, containing 0.1% sodium dodecyl sulfate [Laemelli, Nature, 227, 680 (1970).]. After electrophoresis for 3 hours at 30 milliamperes, the proteins in the gel were transferred electrophoretically to nitrocellulose paper. Protein binding sites on the paper were quenched with PBS containing both BSA (5%) and ovalbumin (5%) for one hour at room temperature. Thereafter, the paper was overlaid with the anti-polypeptide antiserum (1:100 dilution in PBS containing 2% of both BSA nd ovalbumin) for one hour. After washing, the paper was developed with the 125 I-labelled protein A (1 mCi/mg, 2 x 10 5 cpm/ml) for another hour. After extensive washing, the paper was dried and finally exposed to XAR-5 film (Eastman Kodak Co., Rochester, NY) overnight at -70°C. 7. Induction of the Anti-peptide Antibody After receiving two subcutaneous injections of polypeptide-KLH conjugates in CFA, and one injection of glutaraldehyde cross-linked polypeptide in incomplete Freund's adjuvant, the rabbits were bled and the sera were analyzed for anti-polypeptide activity by the ELISA method. As shown in Table 2, sera from both immunized rabbits contained anti-polypeptide antibody detectable at dilutions as high as 1:100,000. Control sera from normal rabbits did not bind significantly to the polypeptide coated plates. TABLE 2 INDUCTION OF ANTI-IDIOTYPE ANTIBODIES BY A POLYPEPTIDE SUBSTANTIALLY CORRESPONDING TO THE SECOND HYPERVARIABLE REGION OF MONOCLONAL HUMAN IgM RHEUMATOID FACTOR (Sie) 3 Absorption at 405 nanometers (xlO ) Serum Dilution lo '3 lo "4 10 "5 Control Normal Rabbit 25 0 0 4 Immune Rabbit 1 1023 497 95 5 Immune Rabbit 2 937 530 85 0 The activities of polypeptide-induced anti-idiotype antibodies (as described above) of two immune rabbit sera were assayed as described herein by a solid phase ELISA on a polypeptide-coated polyvinyl chloride icrotiter plate. Duplicate microtiter wells were coated with the peptide (100 micrograms per milliliter of BBS) and various dilutions of the rabbit antisera were added. Control wells contained buffer only. After incubation for three hours followed by washing, the amount of bound antibody was determined with alkaline phosphatase conjugated anti-rabbit IgG. The absorption at 405 nanometers of the enzyme substrate was measured after one hour. 8. Reactivity of Anti-polypeptide Antibody with the Intact antibody Molecule IgM-RF ' (Sie) The anti-polypeptide antisera were assayed for direct binding to plates coated with intact IgM-RF (Sie) ) . Table 3 (A and B) shows that both anti-polypeptide antisera, but not control sera, reacted with the intact antibody molecule. Even at 1:100,000 dilution, the anti-polypeptide sera bound significantly to the intact IgM protein. TABLE 3 REACTIVITY OF THE POLYPEPTIDE-INDUCED ANTI-IDIOTYPE ANTIBODY WITH THE INTACT IgM-RF (Sie) ANTIBODY MOLECULE* 3A Absorbance at 405 nanometers (xlO ) [After 1 hour Incubation at Room Temperature (23°C) ] Serum Dilution 10 " •3 10 " •3 10 " •5 Control Normal Rabbit 35 13 3 14 Immune Rabbit 1 292 106 47 46 Immune Rabbit 2 307 164 75 0 3B 3 Absorbance aatt 405 nanometers (xlO ) [After Overnight Incubation at 4 β C] Serum Dilution 10 " •3 10 " ■ 4 10 " ■ 5 Control Normal Rabbit 96 19 3 14 Immune Rabbit 1 1041 376 .78 • ' 14 Immune Rabbit 1 824 380 75 9 * The solid phase ELISA was performed as in Table 2, except that the wells were coated with 10 micrograms intact IgM-RF per milliliter BBS. The absorbance readings at 405 nanometers were taken after one hour incubation at room temperature (23° C) , and again after overnight incubation at 4 β C. Several IgM-RF paraproteins, including IgM-RF (Sie) , have been shown to interact with rabbit IgG. Kunkel et al. , J. Exp. Med. , 137, 331 (1973). Hence, it was necessary to prove that the interaction between the anti-polypeptide antibody and the IgM-RF (Sie) was due to the specific binding activity of the anti-polypeptide antibody, and not to a non-specific interaction of the IgM-RF with rabbit IgG in the antisera. Table 4 (A and B) shows that the anti-polypeptide antibody bound significantly to isolated heavy chains prepared from IgM-RF (Sie) , which lacked detectable ability to bind rabbit IgG. TABLE 4 REACTIVITY OF THE POLYPEPTIDE-INDUCED ANTI-IDIOTYPE ANTIBODY WITH THE ISOLATED HEAVY CHAIN OF IgM-RF (Sie)* 4A 3 Absorbance at 405 nanometers (xlO ) [After 1 hour Incubation at Room Temperature (23°C) ] Serum Dilution lo "3 lo "4 lo "5 Control Normal Rabbit 16 9 3 10 Immune Rabbit 1 437 105 10 11 Immune Rabbit 2 324 92 6 0 4B Absorbance at 405 nanometers (xlO ) [After 1 hour Incubation at Room Temperature (4°C)] Serum Dilution lo "3 lo "4 lo "5 Control Normal Rabbit 40 13 4 11 Immune Rabbit 1 1443 404 67 12 Immune Rabbit 1 1084 319 50 5 * In this determination-, the wells were coated with the isolated heavy chain of the IgM-RF (Sie) protein (10 micrograms protein per milliliter BBS). Otherwise, the conditions were the same as those described for the trial shown in Table 2. Morever, the F(ab') 2 fragments of the anti-polypeptide antibody, but not those of normal rabbit IgG, bound to the intact IgM-RF (Sie) protein. (See Table 5) . TABLE 5 ADSORPTION AND ELU ION OF THE IgM-RF (Sie) BINDING ACTIVITY FROM A POLYPEPTIDE-COUPLED AFFINITY COLUMN Antigens Coated: BSA Polypeptide IgM-RF (Sie Samples: Absorbance at 405 nanometers (xlO Original 17 1900 587 Effluent 33 374 47 Eluate 28 1900 459 Normal Rabbit IgG 59 136 89 Crude F(ab') 2 fragments (200 milligrams) of the polypeptide anti-idiotype antibody were added to a 3 milliliter peptide-coupled column (5 mg/ml gel) . After, incubation for 15 minutes at room temperaturee (23 β C) , the effluent was collected. After washing, the bound material was eluted with 0.1 molar glycine-HCl (pH3) , and was neutralized. All samples were assayed at a concentration of 25 microgram per milliliter to microtiter wells coated with BSA, the polypeptide, or intact IgM-RF (Sie) in the standard ELISA procedure as described above. 9. The Anti-Peptide Antibody Recognizes A Peptide-Determined Epitope on IgM-RF (Sie) To prove that the antibody bound to a specific polypeptide-determined epitope on the intact IgM-RF (Sie) molecule, two types of studies were performed. First, as shown in Table 5, most of the IgM-RF (Sie) binding activity was adsorbed by, and eluted from, a polypeptide-coupled immunoadsorbent column. Second, the antibody binding activity to IgM-RF (Sie) coated plates was inhibited completely by the free polypeptide in solution (Figure 4) i Under the same conditions , a control polypeptide corresponding to the third hypervar iable region of the heavy chain of the monoclonal IgM-RF (Wol) , did not have s ignificant inhibitory activity, even at a 1, 000-fold higher concentration. 10. The Anti-polypeptide Antibody Recognizes a Pr ivate Idiotope on IgM-RF (Sie) The observation that the anti-polypeptide antibody bound efficiently to isolated IgM-RF (Sie) heavy chains enabled development of a sensitive protein blotting method for the detection of the epitope- bearing IgM-RF that avoided non-specific interactions between human IgM-RF and rabbit IgG. A panel of IgM-RF paraproteins, as well as pooled human IgG (Cohn Fraction II) , were fractioned by SDS polyacrylamide gel electrophoresis under reducing conditions, and then were transferred onto nitrocellulose paper. After incubation with the anti-polypeptide antibody and final development with 125I-labeled protem-A, autoradiographs were prepared. Figure 5 shows that the anti-polypeptide antibody reacted with the heavy chain of IgM-RF paraproteins, two of which (Glo and Teh) react with a monoclonal antibody against a cross-reactive (public) idiotype on the Sie molecule (Carson et al. , Mol. Immunol. , supra) . Notably, the anti-polypeptide antibody did not react detectably with the heavy chains of pooled human IgG. These results demonstrate that the anti-polypeptide-antibody recognizes a private idiotype on the ijeavy chain of IgM-RF (Sie) . -so¬ il. Polypeptide-Induced Antibodies Recognize a Public Idiotype of Human RFs After receiving two subcutaneous injections of PSL2-KLH conjugates .and one injection of glutaraldehyde cross-linked polypeptide, the sera were obtained one week after the last injection and were analyzed for anti-polypeptide activity by the herein described ELISA techinique. As shown in Table 6(A) , both immune sera contained high titers of anti-PSL2 antibodies. Coated sera pooled from normal rabbits did not bind. significantly to the polypeptide-coated plates. In addition, the immune sera did not react with polypeptide PSH3 which was used as a control. Thereafter, the anti-polypeptide antisera were assayed for reactivity with IgM-RF Sie. Table 6(B) shows that both antisera, but not the control sera, reacted speciical ' ly with the intact antibody molecules. However, the reactivities of both antisera with IgM-RF Sie were relatively weak. This suggests that either only a small fraction of PSL2-induced antibodies reacted with the intact immunoglobulin, or that the interactions between the PSL2-induced antibodies and the Igm-RF Sie were of very low affinity. TABLE 6 INDUCTION OF ANTI-RF ANTIBODIES WITH POLYPEPTIDE 1 2 (λ) Detection of Polypeptide-Inducβd Anti-idiotype Antibodies. ' Absorbance at 405 nanometers (xlO ) Polypeptide (PSL2) Serum Dilution lo" 3 lo" 4 lo "5 Control Normal Rabbit 23 6 3 5 Immune Rabbit 1 1036 302 53 15 Immune Rabbit 2 948 370 54 1 2 3 (B) Detection of RF-Inducβd λnti-Idiotype Antibodies. Absorbance at 405 nanometers (xlO ) RF (IgM-RF Lay) Serum Dilution lo "3 lo "4 lo "5 Control Normal Rabbit 35 13 3 4 Immune Rabbit 1 136 28 5 12 Immune Rabbit 2 92 21 13 14 1. The polypeptide-induced anti-idiotype antibody activities were assayed by a solid-phase ELISA on a polypeptide-coated microtiter plate. Various dilutions of the sera and control (buffer only) were added to veils in duplicate and incubated for 3 hours at room temperature (23*C.). Subsequently, the bound antibodies were quantitated with the en.eyme-conjugated anti-rabbit Ig β and the substrate. The absorptions at A 4Q5 after 1-hour at room temperature were determined. 2. The specificities of both assays were shown by that immune serum did not react with the control PSH3 (A) and the control IgM-RF Lay (B) respectively (data no shown). 3. Same as in Mote 1 above, except that the wells were coated with the IgM-RF Sie. Since PSL2 includes an amino acid residue sequence that corresponds to a hypervariable region shared by L chains of two human monoclonal IgM-RFs (Andrews et al. , supra) , the reactivity of the PSL2-induced antibody was determined against a panel of human monoclonal RFs. Table 7 (lines 2 and 3) shows that PSL2-induced antibodies react with Ig-RF Glo, and to a lesser degree with IgM-RF Po , but not IgM-RF Lay. Again, the binding was extremely weak. TABLS 7 REACTIVITIES OF PSL2-INDUCED ANTIBODIES WITH CERTAIN HUMAN MONOCLONAL IgM-RFs 1 Absorbance at 405 nanometers (xlO ) Coating RF Sie Glo Pom Lay Samples: Anti-IgM 2 568 735 859 315 Immune serum Initial bleeding 38 4 109 23 0 Subsequent bleeding 116 ND 23 ND 1. Same as in Table 6(B), except: 1) the listed RFs were coated at 2 micrograms RF per milliliter BBS. Immune sera were assayed at the 1:1000 dilution, and the absorbance at 405 nanometers was measured after overnight incubation in a cold room at 6 * C.ι 3) anti-IgM (from the rabbit immunized with IgM-RF Sie, and the absorbance at 405 nanometers was measured after 1-hour incubation at room temperature. 2. Anti-IgM was used to measure the relative quantities of each IgM-RF. 3. The rabbit (#1) was initially bled one week after the first injection of glutaraldehyde cross-linked PSL2. Subsequently, the rabbit was further boosted with two more injections (one of cross-linked PSL2 and then one of PSL2-KLH conjugates) to increase the anti-RF Sie titer, and bled one month after the last injection. 4. The numbers expressed are of the immune serum after subtracting A _ of the control normal rabbit serum. 5. ND-Not determined. It had been shown that several human IgM-RF paraproteins reacted with rabbit IgG [Kunkel et al. , J. Exp. Med., 139, 129 (1974)1. Hence, it was necessary to prove that the interactions between PSL2-induced antibody and those reactive IgM-RFs were due to the specific binding activity of the PSL2-induced antibodies, and not to the non-specific interactions of the human IgM-RFs with rabbit IgG in the antisera. Thus, the reactivity of the PSL2-induced antibody with the isolated chains of these IgM-RFs was determined by the Western blot method (Towbin et al. , supra) . As shown in Figure 7(C) , the PSL2-induced antibodies reacted equally well with the light (L) chains of IgM-RF Sie, Glo and Teh. Due to the extremely small quantity of IgM-RF Teh that we had, only 1/5 equivalent weight of IgM-RF Teh was used. Thus, another Western blot was performed to confirm the antibody reactivity with the RF-Teh [Figures 7(D) and 7(E)]. One set of samples was reacted with anti-IgM antiserum to show the relative quantities of different RFs [Figure 7(D)]; and autoradiographs were developed for a 3-day period. These results demonstrated that PSL2-induced antibodies reacted with. RF-Teh. In addition, the antibody reacted very weakly with the L chains of IgM-RF Pom and pooled IgG. However, most importantly, it reacted neither with the L chain of the IgM-RF Lay, nor with the heavy (H) chains of all IgM-RFs. In contrast, PSH3-induced antibodies reacted only with the H chain of the IgM-RF Sie. These results collectively demonstrated that PSL2-induced antibodies recognized a public idiotype on the L chains of some human IgM-RFs. 12. The Structural Correlate of the RF Public Idiotype Defined by the PSL2-Induced Antibodies To prove that PSL2-induced antibodies bound to a specific PSL2-determined idiotype on the reactive IgM-RFs, inhibitions of the antibody bindings to both intact RF (Sie) , and the isolated L chain of RF-Glo by the PSL2 peptide were determined. Figure 8(A) shows that the antibody binding to RF-Sie was completely inhibited by the free PSL2 peptide in solution, while the binding was not affected at all by the control PSH3 at the same concentrations (data not shown). Moreover, the control PSH3 at 5000 ng/ml completely inhibited the bindings of PSH3-induced antibodies to RF-Sie. Thus, these data indicated that the PSL2-induced antibodies recognized a specific PSL2-determined idiotype on the RF-Sie. Subsequently, isolated L chains were prepared from the IgM-RF Glo. As expected, PSL2-induced antibodies reacted with the L chains of RF-Glo [Figure 8(B)]. Moreover, the binding was completely inhibited by the free PSL2 in solution, but not PSH3 [Figure 8(B)]. This suggests that the L chains of RF-Sie and RF-Glo share an homologous second complementarity-determining region (CDR-2) , and that the L chain-CDR-2 is the structural correlate of the RF public idiotype defined by the PSL2-induced antibody. 13. The Anti-RF Activity Resides in the Anti-peptide Antibody To further characterize PSL2-induced antibodies, the IgG fraction was prepared from the antiserum containing high titer of anti-RF activity (e.g., the bleeding from immune rabbit #1 one month after one more injection of glutaraldehyde cross-linked polypeptides and another injection of polypeptide-protein conjugates) . Then, the IgG preparation was adsorbed with BSA to remove non-specific binding activities, and the specific antibodies were purified by a PSL2-coupled column. Table 8 shows that anti-RF activities were adsorbed by, and eluted from the PSL2-coupled column, indicating that anti-RF antibodies of the immune sera were induced by peptide directly, but not indirectly through some pathways of the immune network. TABLΞ 8 ADSORPTION AND ELUTION OF THE ANTI-RF ACTIVITY FROM A PSL2-COUPLED AFFINITY COLUMN 1 Absorbance at 405 nanometers (xlO ) Antigens Coated Bovine Serum Albumin Polypeptide IgM-R (BSA) (PSL2) Samples Original 24 1319 303 BSA-adsorbed 0 1214 250 BSA, peptide adsorbed 0 38 25 Eluate 12 1859 730 Eluate (1 microgram/ 0 1616 375 milliliter) 1. An IgG fraction (100 milligrams) of the antiserum was first adsorbed with a 3 ml BSA-coupled column (5 mg/ml gel) , and then loaded onto a 3 ml PSL2-coupled column (1.6 mg/ml gel). After incubation for 15 minutes at room temperature (23°C), the effluent was collected. Subsequently, the column was washed extensively, and the bound material was eluted with 0.1 M glycine-HCA at pH 2.5. 2. Unless indicated otherwise, all samples at a concentration of 10 micrograms per milliliter were assayed as described with reference to Table 6(B). Furthermore, Table 9 shows that the affinity-purified anti-PSL2 antibody reacts strongly with Sie and Glo but reacts weakly with Pom. TABLE 9 REACTIVITIES OF THE AFFINITY-PURIFIED ANTI-PSL2 ANTIBODIES WITH CERTAIN HUMAN MONOCLONAL IgM-RFs 1 3 Absorbance at 405 nanometers (xlO ) Coιating RF Sie Glo Pom Anti-PSL2 Antibody 1136 1900 256 Antibody-depleted I :gg 57 393 56 Differential bindinιgg 1179 1507 200 1. The anti-PSL2 antibody (the eluate in Table 8) and the antibody-depleted Ig (the peptide- adsorbed fraction in Table 8) were assayed for their reactivities with various IgM-RFs, coated onto microtiter plates at 2 micrograms per the absorbance at 405 nanometers was determined. 2. The absorbance at 405 nanometers was determined after overnight incubation at room temperature (23 β C). 3. Differential binding equal to (A 4Q5 of antibody - A 405 of antibody-depleted immunoglobulin) . 14. The Anti-peptide Antibody Reacts with Intact Antibody Molecules in their Native Forms During this study, it was suspected that the denatured IgM-RFs coated onto wells were responsible for interactions with anti-peptide antibodies. To rule out this possibility, it was shown that IgM-RF Sie in liquid phase was still recognized by anti-peptide antibodies. Table 10 shows that enzyme-conjugated IgM-RF Sie (AP-lgM-RF Sie) bound to wells precoated with anti-PSL2 antibodies, but not the rabbit IgG depleted of anti-PSL2 antibodies. TABLE 10 NATIVE IgM-RF SIE (IN THE LIQUID PHASE) REACTS WITH POLYPEPTIDE-INDUCED ANTI-IDIOTYPE ANTIBODIES COATED ONTO WELLS 3 Absorbance at 405 nanometers (xlO ) Proteins Coated Anti-peptide Antibody- antibody depleted Ig AP-IgM Sie: (Micrograms/Milliliter) 10 1763 80 5 1057 40 2.5 603 22 1. Polypeptide-induced anti-idiotype antibodies (the eluate of Table 8) and antibody-depleted IgG (the peptide-adsorbed IgG of Table 8) at 8 micrograms/milliliter were used to coat separate wells. 2. IgM-RF Sie was labeled with alkaline phosphatase by glutaraldehyde. 3. AP-lgM-RF Sie of specified concentrations were distributed to wells in duplicate and the plate was incubated for 3 hours at room temperature (23°C) . After washing, the substrate was added to wells, and the absorbance at 405 nanometers was measured after 1 hour at room temperature (23 β C). " Furthermore, as shown in FIGURE 9, the binding of AP-lgM-RF Sie to the bound anti-PSL2 antibodies was specifically inhibited by the PSL2, but not the control PSH3. This demonstrates that the binding of the intact IgM-RF Sie to anti-PSL2 antibodies is due to its PSL2-determined epitope, and is not due to its RF activity. Taken together, these data demonstrate that the anti-PSL2 antibody did react specifically with the PSL2-determined idiotype on an intact IgM-RF Sie in its native form. V. Diagnostics The above polypeptides can also be used as a portion of a diagnostic composition for detecting the presence of antigenic proteins and antibodies. A diagnostic reagent system embodying this invention is useful for the determination of the presence of an increased amount of protein compared -to the amount of that protein normally present. This system comprises in separate containers (a) a first reagent and (b) a second, reagent, both in biologi¬ cally active form, along with an indicating group. The first reagent contains one of the before-described synthetic polypeptides, a combination of such polypeptides, or conjugates prepared therefrom. The second reagent includes polyamides containing idiotypic regions of antibodies raised to the synthetic polypeptides or their conjugates. The idiotype-containing polyamides of the second reagent may be substantially intact antibodies or Fab or F(ab') 2 antibody fractions whose preparations were described before. An indicating group may also be provided to the system and can be initially bound to or free from either of the two reagents. Admixture of predetermined amounts of the first and second reagents in the presence of a predetermined amount of a body component to be assayed results in an immunoreaction. The degree or amount of the immunoreaction so produced is different from a known immunoreaction amount when an increased amount of protein is present in the body component. The amount of immunoreaction is typically diminished when an increased amount of the protein is present in the body component, compared to the usual amount present. Another diagnostic system comprises the before-discussed anti-idiotype antibodies in biochemically active form and an indicating means. In this system, the anti-idiotype antibodies or their Fab or F(ab') 2 fractions react with an antigen in a sample to be assayed to form an immuno-reactant whose presence is signalled by the indicating means. The above system may also include second antibodies raised to antibodies of the same class and from the same species as the anti-idiotype antibodies as part of the indicating means. For example-, where the anti-idiotype antibodies are raised in rabbits, commercially available goat anti-rabbit antibodies may be used. Such second antibodies conveniently include a label such as a linked enzyme like horseradish peroxidase or a radioactive element like 125 I as the signal indicator. Exemplary diagnostic reagent systems include enzyme-linked immunosorbent assays (ELISA) wherein the indicator group is an enzyme such as horseradish peroxidase which is bound to the above antibody or another antibody, and radioimmunoassays in which the indicating group is a radioactive element such as 1 5 I present in either the synthetic polypeptide or the antibody raised thereto. VI. Discussion The antigen binding site of an antibody is formed from the three dimensional folding of the variable regions of the heavy and light chains. Padlan et al. , Nature, New Biol, 245, 165 (1973) . Diversity in antibody specificity is derived from variation in the primary (linear) amino acid sequences of the variable regions. The primary amino acid sequence dictates the three dimensional folding pattern. Thus, different "shape" binding sites with different active residues in the binding site are generated from different primary amino acid sequences. There are three regions of extreme variability .in the primary sequence within the variable region. These sites are termed hypervariable regions. Capra et al. , Proc. Nat. Acad. Sci. U.S.A., 71, 845 (1974) . As described herein, the anti-idiotype antibodies of the present invention were raised against polypeptides that correspond to sequences in the heavy chain of a particular immunoglobulin. The antibodies raised could recognize and distinguish the corresponding individual idiotype, for example, in the third hypervariable region of that immunoglobulin. The data further strengthen the generally accepted conclusion that the idiotope is defined principally by the heavy chain. Notwithstanding, it is not possible to exclude the light chains as playing a role in the expression of individual idiotopes. The individual idiotope of the J558, for example, is not expressed by separated J558 heavy and light chains nor by J558 heavy chains reconstituted with an inappropriate light chain as described in Carson et al. , Proc. Natl. Acad. Sci. USA, 2P_, 235. (1973). Thus, in the native immunoglobulin or Fab or F(ab') 2 fragments, a light-heavy chain interaction may be required to stabilize the heavy chain variable region in the -63- conformation necessary for expression of the particular idiotope. The present invention can be applied to manipulating the immune response to cure or combat autoimmune diseases. In a like manner, this invention can be used to reduce transplant rejections. Such application of the invention is further explained below. Invasion by an antigenic substance generally results in a polyclonal response to the antigen as described by Hansburg et al. , J.- Immunol. , 194, 1406 (1977); Briles et al. , J. Exp. Med., 152, 151 (1980) and Ceney et al. , J. Immunol. , 128, 1885 (1982) . A polyclonal response is likely to occur for two reasons. First, an antibody or the receptor on a B-cell has a precise specificity. However, antibodies and B-cell receptors have the capability of reacting to antigenic determinants which do not exactly match the binding site "shape" but are related in "shape". This is known as cross-reactivity. Thus, a particular antigen is likely to fall within the range of cross-reactivity of several B-cell clones. Consequently, several antibodies with different variable regions are produced against an antigenic determinant. Second, an antigen is likely to possess several antigenic determinants. Each of these antigenic determinants is likely to elicit its own antibody response, thereby producing antibodies that contain different variable regions. In summary, invasion by an antigenic foreign substance results in a polyclonal antibody response. These antibodies do not all share identical variable regions. This in turn results in a variety of idiotypes being expressed by the antibodies directed against an antigen. It was desirable to raise anti-idiotype antibodies to the individual idiotype found in the third hypervariable region of J558 and M104 myeloma proteins, as previously stated. Two different sets of synthetic polypeptides were investigated. The first set included the first seven adjacent amino acid residues in the J segment and 3 adjacent amino acids in the V segment. This synthetic polypeptide was designed to be long enough to ensure the eliciting of an anti-polypeptide immune response. The synthetic polypeptides were designated hV3M and hVBJ and correspond respectively to the M104 and J558 " myeloma proteins. The amino acid residue sequences selected for« hV3M and hV3J polypeptide result in a substantial portion of the sequence encoded by the Jl gene segment being common to both polypeptides. Thus, there was the possibility that much of the anti-polypeptide response would be directed against this common sequence. This could possibly result in an obscuring of the antibody activity that is specific for the different D-segments. The second set of synthetic polypeptides used in that study includes the minimum cognate sequence necessary to form an antigenic determinant as described by Lerner et al. , Nature, 299, 592 (1982). These synthetic.polypeptides were designated 3MN and 3JN and correspond respectively to the M104 and J558 myeloma proteins. Antisera were raised against the various synthetic polypeptides. The ability of these antisera to distinguish between the two myeloma proteins was determined. Eight of the twelve antisera were able to distinguish between the two myeloma proteins in a denatured form (Figure 2) . In addition, these antibodies displayed a high level specificity for the natural protein that corresponds to the immunizing polypeptide. Six of the twelve antisera could distinguish between the natural myeloma proteins (i.e. not denatured) and exhibited a high level of specificity for the protein corresponding to the immunizing agent. In summary, at least half of the immunized animals produced antibodies capable of descriminating the individual idiotypes of the M104 and J558 proteins, irrespective of whether the proteins were native or denatured. Thus, these results show that anti-idiotype antibodies specific for a predetermined particular idiotypic antigenic determinant can be raised using synthetic polypeptides. That is, the antibodies distinguished between two proteins in a specific manner corresponding to the immunizing polypeptide. Furthermore, these anti-idiotype antibodies have the capability of descriminating between idiotypes which differ by as few as two amino acid residues. Three of the antisera (numbers 5, 8 and 10) appear to have absolute specificity within experimental limits for their target idiotype. The other antisera which distinguished the two myeloma proteins displayed a high level specificity for their target idiotype. It may be possible to increase the frequency of antisera with absolute specificty by utilizing shorter cognate sequences and spacers; as was done with immunizing polypeptides 3MN and 3JN. Not enough animals have yet been immunized to make the appropriate comparison. . It should also be noted that antibodies raised against the shorter cognate sequence polypeptides, 3MN and 3JN, were generally of lower titre than the antibodies raised against synthetic polypeptides with a longer cognate series, hV3M and hV3J (data not shown) . The binding site affinity of the various antisera for their corresponding immunizing polypeptide was determined using enzyme linked immunosorbant assay as described in Green et al. , Cell, 28, 477 (1982) . All the polypeptides induced antibodies which bound the immunizing polypeptide. However, the antibodies elicited by the 3MN and 3JN were generally of lower titre. It is not clear whether this is due to the use of a shorter conjugate. As also described herein, a synthetic polypeptide, corresponding to the third hypervariable region of the heavy chain of the human monoclonal IgM-RF Sie, has also been used to induce the production of an anti-hypervariable region antibody. The anti-idiotype antibody binds to the intact immunoglobulin M molecule (Sie) and to its isolated chains, but does not bind to other IgM paraproteins or to pooled human IgG. Moreover, the binding of the antibody to the intact IgM was inhibited specifically by the free polypeptide. These results also demonstrate that a specific anti-idiotype antibody of predefined specificity; i.e., that bind to a particular idiotypic antigenic determinant, can be induced by a synthetic polypeptide, and that such an anti-idiotype antibody recognizes an idiotypic antigenic determinant formed by the known hypervariable region. In one embodiment of the present invention, that predefined specificity does not extend beyond recognition of a private idiotype of a single antibody molecule. In a preferred embodiment, however, the use of synthetic polypeptides to induce the production of anti-idiotype antibodies has been extended to generate an anti-idiotype antibody of a public or cross-reactive idiotype. Among human monoclonal IgM rheumatoid factors (IgM-RF) , two major cross-reactive idiotypes (e.g., Wa and Po) have been described. [Kunkel et al. , J. Exp. Med., 137, 331 (1973)]. The Wa group includes 60% of monoclonal IgM-RFs, and the expression of the Wa cross-reactive idiotype seems to depend on the L chains of reactive IgM-RF. [Kunkel et al. , J. Exp. Med. , 139, 128 (1974) and Andrens et al. , supra.] . A murine monoclonal antibody (designated mab 17-109) has been prepared that reacts with two cross-reactive (+) id,iotypic IgM-RFs (e.g., Sie and Glo, but not with two Wa-cross-reactive (-) idiotypic (e.g.. Lay and Pom). [Carson et al. , Mol. Immunol. , 20, 1983)]. In addition,, mab 17-109 reacted with the light chains, but not with the heavy chains, of Wa-cross-reactive (+) idiotypic IgM-RFs. A comparison of the reported amino acid sequences of the L chains of Wa-cross-reactive (+) idiotypic IgM-RFs (See Figure 6) indicates that these L chains have the same amino acid sequence in the second hypervariable region. Thus, a synthetic polypeptide corresponding to that region was prepared and was used to induc the production of an anti-idiotype antibody of a cross-reactive hypervariable region. The foregoing is intended.as illustrative of the present invention but is not limiting. Numerous variations and modifications, can be effected without departing from the spirit and scope of the novel concepts of the invention. It is to be understood that no limitation with respect to the specific antibodies, compositions and uses described herein is intended or should be inferred.

Claims: WHAT IS CLAIMED IS: 1. A synthetic polypeptide having an amino acid residue sequence that substantially corresponds to an amino acid residue sequence of an idiotypic antigenic determinant of an immunoglobulin, said synthetic polypeptide having the capacity alone, as a polymer or as a conjugate of said polypeptide bound to a carrier, when injected into a host in an effective amount and in a physiologically tolerable vehicle of inducing the production of antibodies to said antigenic determinant of said immunoglobulin. 2. The synthetic polypeptide according to claim 1 wherein said synthetic polypeptide contains at least about six amino acid residues but less than about forty amino acid residues. 3. The synthetic polypeptide according to claim 1 wherein said synthetic polypeptide contains from about 8 to about 20 amino acid residues. 4. The synthetic polypeptide according to claim 1 including the sequence of amino acid residues, taken from left to right and in the direction from amino-terminus to carboxy-terminus, represented by a formula selected from the group consisting of: - CysAlaArgAspTyr(Arg)Asp(Tyr)TrpTyr PheAspValTrpGly; GluGluCysProProProAlaArgAsp Tyr (Arg)Asp(Tyr)TrpTyrPhe; GluTrpLysGlyGlnValAsnValAsn ProPheAspTyr; GluTrpLysGlyGlnValAsnValAsn ProPheAspTyrGlyGlyCys; and TyrGlyAlaSerSerArgAlaThrGlylleProAspArgCys wherein each amino acid residue in parentheses is an alternative to the immediately preceding amino acid residue. 5. The synthetic polypeptide according to claim 1 wherein said immunoglobulin is a human rheumatoid factor of class I M. 6. A vaccine against infection by a pathogen having an immunoglobulin with a particular idiotypic antigenic determinant comprising an effective amount of a synthetic polypeptide having an amino acid residue sequence that immunologically corresponds substantially to an amino acid sequence of an antigenic determinant of an immunoglobulin and a physiologically acceptable diluent, said vaccine, when introduced into a host, being-capable of inducing the production of antibodies in the host that immunoreact with said antigenic determinant and ■ protect the host from infection. 7. The vaccine according to claim 6 wherein said synthetic polypeptide is bound to a carrier selected from the group consisting of keyhole limpet hemocyanin, keyhole limpet hemocyanin in incomplete Freund's adjuvant, alum, keyhole limpet hemocyanin-alum absorbed, keyhole limpet hemocyanin-alum absorbed-pertussis, edestin, thyroglobulin, tetanus toxoid and tetanus toxoid in incomplete Freund's adjuvant. 8. Antibodies raised in an animal host to a synthetic polypeptide having an amino acid sequence that immunologically corresponds substantially to an amino acid sequence of an idiotypic antigenic determinant of an immunoglobulin, said antibodies having the capacity to immunoreact with said antigenic determinant and protect the host from said immunoglobulin. 9. A diagnostic system for assaying for the presence of an antigenic determinant of an immunoglobulin comprising in biochemically active form the antibodies of claim 8, said antibodies immunoreacting with an admixed sample to be assayed to form an immunoreactant whose presence is signalled by an indicating means. 10. The diagnostic system according to claim 9 further including an indicating means comprising enzyme-linked second antibodies, said second antibodies being raised to antibodies of the same class and from the same species as the first named antibodies, and signalling said immunoreaction by binding to said first named antibodies present in said immunoreactant, said signal being indicated by the reaction of said linked enzyme with an added substrate. 11. The diagnostic system according to claim 9 wherein said indicating means comprises a radioactive element bonded to said antibodies and said immunoreaction causes precipitation of said immunoreactant containing said radioactive element. 12. A diagnostic system for assaying for the presence of an idiotypic antigenic determinant of an immunoglobulin in a body component comprising in separate containers (a) a first reagent that contains in biologically active form a synthetic polypeptide containing a sequence of about six to about forty amino acid residues that immunologically corresponds substantially to an amino acid residue sequence of said antigenic determinant, said polypeptide, when linked to a carrier as a conjugate and introduced in an effective amoun as a vaccine into a host animal, being capable of inducing production of antibodies in the host that immunoreact with said antigenic determinant and protect the host from said immunoglobulin; and (b) a second reagent that contains in biochemically active form an anti-idiotype antibody that immunoreacts with said synthetic polypeptide; along with a means for indicating the presence of an immunoreaction between said first and second reagents; said first and second reagents, when admixed in predetermined amounts in the presence of a predetermined amount of body component to be assayed, providing an amount of immunoreaction signalled by said indicating means, the amount of said immunoreaction being different from a known immunoreaction amount when an immunoglobulin including said antigenic determinant is not present in said body component. 13. A method of forming an anti-idiotype antibody comprising the steps of: (a) administering to a host a synthetic polypeptide in an amount sufficient to induce the production of antibodies to an antigenic determinant of an immuno lobulin, said synthetic polypeptide having an amino acid residue sequence that substantially corresponds to the amino acid residue sequence of an idiotypic antigenic determinant of said immunoglobulin; and (b) recovering the anti-idiotype antibodies so produced. 14. The method according to claim 13 wherein said idiotypic antigenic determinant is a variable or hypervariable region of said immunoglobulin. 15. A method for assaying for the presence of an idiotypic antigenic determinant of an immunoglobulin in a sample comprising: (a) providing a synthetic polypeptide of claim 1; (b) admixing a predetermined amount of said polypeptide with a predetermined amount of sample to be assayed for the presence of the idiotypic antigenic determinant to which the polypeptide binds; (c) maintaining that admixture for a period of time sufficient for said polypeptide to bind to idiotypic antigenic determinant present in the admixed sample; and (d) determining the amount of binding between said synthetic polypeptide and said idiotypic antigenic determinant of said immunoglobulin.

Inventors: CARSON DENNIS A, CHEN POJEN P, FONG SHERMAN, HOUGHTEN RICHARD, LERNER RICHARD A, MCMILLAN SEAMUS L H, VAUGHAN JOHN H, CARSON, DENNIS, A., CHEN, POJEN, P., FONG, SHERMAN, HOUGHTEN, RICHARD, LERNER, RICHARD, A., MCMILLAN, SEAMUS, L., H., VAUGHAN, JOHN, H.
Applicants: SCRIPPS CLINIC RES, SCRIPPS CLINIC AND RESEARCH FOUNDATION
Application year: 1984
Main classification: G01N33
IPC codes: A61K39, C07K14, C07K16, C07K19, C12N15, C12P21, G01N33